Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0131 • ACR Convergence 2021
Association of Numeracy with Medication Non-Adherence in Systemic Lupus Erythematosus
Mithu Maheswaranathan¹, Amanda Eudy², Ann Barr², Catherine Howe³, Stacy Bailey⁴, Susan Hastings¹, Jennifer Rogers², Jayanth Doss², Lisa Criscione-Schreiber¹, Rebecca Sadun², Megan Clowse⁵ and Kai Sun¹, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University Hospital, Durham, NC, ⁴Northwestern University, Evanston, IL, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Over 33% of U.S. adults have limited health literacy or numeracy. Limited health literacy and numeracy have been associated with higher disease activity and…
Abstract Number: 0330 • ACR Convergence 2021
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
Thaisa Cotton¹, Marvin Fritzler², May Choi³, Boyang Zheng⁴, Omid Zahedi Niaki⁵, Louis-Pierre Grenier⁵, Evelyne Vinet⁶, Christian Pineau¹, Luck Lukusa⁷, Fares Kalache⁵ and Sasha Bernatsky¹, ¹McGill University, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University Health Centre, Mont Royal, QC, Canada, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: To determine if a serologic phenotype can be identified in SLE patients with myositis and/or ILD.Methods: Adult SLE patients (without myositis or ILD at…
Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Emily Littlejohn¹, Lingxuan Kong², Kelly Speth², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
Abstract Number: 0523 • ACR Convergence 2021
Transcriptional Subsetting of SLE Patient Cohorts Based on Metabolic Pathway Activity
Diogo Camacho, Jennifer Swantek, Keng Soh, Jurre Kamphorst, Vivek Kaimal, John Monroe and Edward Driggers, Rheos Medicines, Inc, Cambridge, MA
Background/Purpose: Systemic lupus erythematosus is a highly complex, heterogeneous, autoimmune disorder, with diverse clinical presentation and innate and adaptive immune system involvement. There is a…
Abstract Number: 0613 • ACR Convergence 2021
Racial/Ethnic Disparities in Prescription Medications in a Large Urban Medical Center
J. Thomas Berry, William Galanter, Alia Welsh, Sandra Folarin, Reginald Woods and Huan Chang, UIC Medical Center, Chicago, IL
Background/Purpose: African Americans and Hispanics with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) continue to have worse disease-related health outcomes relative to Whites. This…
Abstract Number: 0784 • ACR Convergence 2021
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America
Laura Cannon¹, Scott Wenderfer², Laura Lewandowski³, Jennifer Cooper⁴, Beatrice Goilav⁵, Andrea Knight⁶, Aimee Hersh⁷, Stacy Ardoin⁸ and Rebecca Sadun¹, ¹Duke University, Durham, NC, ²Baylor College of Medicine, Houston, TX, ³NIAMS, NIH, Rockville, MD, ⁴University of Colorado/Children's Hospital Colorado, Denver, CO, ⁵Children's Hospital at Montefiore, Bronx, NY, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷University of Utah, Salt Lake City, UT, ⁸Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) has higher rates of lupus nephritis (LN) than adult-onset SLE, often requiring intensive immunosuppression. This study examined North American…
Abstract Number: 0871 • ACR Convergence 2021
The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Alejandra Londono Jimenez¹, Mohammad Hashim Mustehsan¹, Ana Valle², Jammie Law³, Shudan Wang², Maria Auxiliadora Salgado Guerrero⁴, David Briceno¹ and Anna Broder¹, ¹Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Montefiore Medical Center, Bronx, NY, ⁴Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Current guidelines recommend use of hydroxychloroquine (HCQ) at doses not exceeding 5mg/kg based solely on the increased risk of retinopathy at higher doses. This…
Abstract Number: 0888 • ACR Convergence 2021
Disease Flares in Lupus Are Concordant with Ruminococcus Blautia Gnavus Blooms Within Unstable Gut Microbiota Communities
Doua Azzouz¹, Ze Chen¹, Zhi Li¹, Jing Deng¹, Peter Izmirly¹, David Fenyo¹, Jill Buyon¹, Alexander Alekseyenko² and Gregg Silverman¹, ¹NYU Grossman School of Medicine, New York, NY, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus is the archetypic systemic autoimmune disease in which dysbiosis in the gut microbiome has been postulated to contribute to disease development…
Abstract Number: 0989 • ACR Convergence 2021
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users
April Jorge¹, Ronald Melles², Carol Conell³, Na Lu⁴, Michael Marmor⁵, Lucy Young⁶, Natalie McCormick¹, Yuqing Zhang⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Redwood City Medical Center, Department of Ophthalmology, Kaiser Permanente Northern California, Redwood City, CA, ³Kaiser Permanente Northern California, Palo Alto, CA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts Eye and Ear Institute, Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases; however, the known risk factors for HCQ retinopathy (its major…
Abstract Number: 1160 • ACR Convergence 2021
Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Diana Meyler¹, Sofia Pedro², Alan Erickson³, Patricia Katz⁴ and Kaleb Michaud³, ¹UNMC, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of California San Francisco, San Francisco, CA
Background/Purpose: Despite being used for more than 70 years as a conventional (cs) DMARD, very little is known about the overall side effect (SE) profile…
Abstract Number: 1268 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods
Melissa Fazzari¹, Marta Guerra², Jane Salmon² and Mimi Kim³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Hospital for Special Surgery, New York, NY, ³Albert Einstein College of Medicine, Larchmont, NY
Background/Purpose: Nearly 20% of pregnancies in patients with Systemic lupus erythematosus (SLE) result in an adverse pregnancy outcome (APO); early identification of women with SLE…
Abstract Number: 1284 • ACR Convergence 2021
One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria
Emma Weeding¹, Andrea Fava², Daniel Goldman³ and Michelle Petri³, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Up to 40% of individuals with lupus nephritis (LN) develop chronic kidney disease (CKD). Biopsy studies have revealed that patients with SLE can have…
Abstract Number: 1301 • ACR Convergence 2021
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab blocks soluble B cell activating factor (BAFF) and is the only to date approved targeted treatment for systemic lupus erythematosus (SLE). Identification of…
Abstract Number: 1462 • ACR Convergence 2021
Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares
April Jorge¹, Christian Mancini¹, Xiaoqing Fu¹, Gary Ho², Yuqing Zhang³, Karen Costenbader⁴ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²New York University, New York, NY, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA, ⁵Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is an important treatment for systemic lupus erythematosus (SLE), known to reduce disease activity and flares. To minimize the risk of toxicity,…
Abstract Number: 1495 • ACR Convergence 2021
Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials
Thomas Vazquez¹, Jay Patel², Daisy Yan³, Emily Keyes⁴, DeAnna Diaz⁵, Yubin Li⁶, Madison Grinnell⁶, Rui Feng⁷ and Victoria Werth³, ¹FIU Wertheim College of Medicine, Virginia Beach, VA, ²Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, ⁷University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Lupus erythematous (LE) is a systemic autoimmune disease with a variety of cutaneous manifestations. Antimalarials are first-line systemic therapy, yet not all patients respond…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].